NEW YORK (GenomeWeb News) – French drug firm Servier has licensed non-exclusive rights to use Cellectis' π10 modified cell lines for high-throughput screening efforts.

The new agreement follows a recently concluded research pact between the firms that began in 2007.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.